DOCSLIB.ORG

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Remdesivir for the Treatment of Covid-19 — Preliminary Report The new england journal of medicine Original Article Remdesivir for the Treatment of Covid-19 — Preliminary Report J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, E. Hohmann, H.Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R.W. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T.F. Patterson, R. Paredes, D.A. Sweeney, W.R. Short, G. Touloumi, D.C. Lye, N. Ohmagari, M. Oh, G.M. Ruiz-Palacios, T. Benfield, G. Fätkenheuer, M.G. Kortepeter, R.L. Atmar, C.B. Creech, J. Lundgren, A.G. Babiker, S. Pett, J.D. Neaton, T.H. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, and H.C. Lane, for the ACTT-1 Study Group Members*​​ ABSTRACT BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coro- The authors’ full names, academic de- navirus disease 2019 (Covid-19), none have yet been shown to be efficacious. grees, and affiliations are listed in the Ap- pendix. Address reprint requests to Dr. METHODS Beigel at the National Institute of Allergy and Infectious Diseases, National Insti- We conducted a double-blind, randomized, placebo-controlled trial of intravenous tutes of Health, 5601 Fishers Ln., Rm. remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory 7E60, MSC 9826, Rockville, MD 20892- tract involvement. Patients were randomly assigned to receive either remdesivir 9826, or at jbeigel@ niaid . nih . gov. (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional *A complete list of members of the ACTT-1 Study Group is provided in the days) or placebo for up to 10 days. The primary outcome was the time to recovery, Supplementary Appendix, available at defined by either discharge from the hospital or hospitalization for infection- NEJM.org. control purposes only. This article was published on May 22, 2020, at NEJM.org. RESULTS A total of 1063 patients underwent randomization. The data and safety monitoring DOI: 10.1056/NEJMoa2007764 Copyright © 2020 Massachusetts Medical Society. board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Pre- liminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received pla- cebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan- Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who un- derwent randomization (27.0%). CONCLUSIONS Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705.) n engl j med nejm.org 1 The New England Journal of Medicine Downloaded from nejm.org on May 26, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved. The new england journal of medicine novel coronavirus, severe acute non-European sites owing to a shortage of match- res piratory syndrome coronavirus 2 ing placebo; the infusions were masked with an A(SARS-CoV-2), was first identified in De- opaque bag and tubing covers to maintain blind- cember 2019 as the cause of a respiratory illness ing. All patients received supportive care accord- designated coronavirus disease 2019, or Covid-19.1 ing to the standard of care for the trial site hos- Several therapeutic agents have been evaluated for pital. If a hospital had a written policy or the treatment of Covid-19, but none have yet been guideline for use of other treatments for Covid-19, shown to be efficacious.2,3 Remdesivir (GS-5734), patients could receive those treatments. In the an inhibitor of the viral RNA-dependent, RNA absence of a written policy or guideline, other polymerase with inhibitory activity against SARS- experimental treatment or off-label use of mar- CoV and the Middle East respiratory syndrome keted medications intended as specific treat- (MERS-CoV),4-7 was identified early as a promis- ment for Covid-19 were prohibited from day 1 ing therapeutic candidate for Covid-19 because through day 29 (though such medications could of its ability to inhibit SARS-CoV-2 in vitro.8 In have been used before enrollment in this trial). addition, in nonhuman primate studies, remdes- The trial protocol was approved by the insti- ivir initiated 12 hours after inoculation with tutional review board at each site (or by a cen- MERS-CoV9,10 reduced lung virus levels and lung tralized institutional review board as applicable) damage. and was overseen by an independent data and To evaluate the clinical efficacy and safety of safety monitoring board. Informed consent was putative investigational therapeutic agents among obtained from each patient or from the patient’s hospitalized adults with laboratory-confirmed legally authorized representative if the patient Covid-19, we designed an adaptive platform to was unable to provide consent. Full details of the rapidly conduct a series of phase 3, randomized, trial design, conduct, oversight, and analyses can double-blind, placebo-controlled trials. Here, we be found in the protocol and statistical analysis describe the preliminary results of the first plan (available at NEJM.org). stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), in which we evaluated treatment with Procedures remdesivir as compared with placebo. Patients were assessed daily during their hospi- talization, from day 1 through day 29. The pa- Methods tient’s clinical status on an eight-category ordinal scale (defined below) and the National Early Design Warning Score was recorded each day.11,12 All Enrollment for ACTT-1 began on February 21, serious adverse events and grade 3 or 4 adverse 2020, and ended on April 19, 2020. There were events that represented an increase in severity 60 trial sites and 13 subsites in the United States from day 1 and any grade 2 or higher suspected (45 sites), Denmark (8), the United Kingdom (5), drug-related hypersensitivity reactions were re- Greece (4), Germany (3), Korea (2), Mexico (2), corded. (See the full description of trial proce- Spain (2), Japan (1), and Singapore (1). Eligible dures in the Supplementary Appendix.) patients were randomly assigned in a 1:1 ratio to receive either remdesivir or placebo. Randomiza- Statistical Analysis tion was stratified by study site and disease se- The primary analysis was a stratified log-rank verity at enrollment (see the Supplementary Ap- test of the time to recovery with remdesivir as pendix, available with the full text of this article compared with placebo, with stratification by at NEJM.org, for details about stratification crite- disease severity. (See the Supplementary Appendix ria). Remdesivir was administered intravenously for more information about the planned statisti- as a 200-mg loading dose on day 1, followed by a cal analysis.) 100-mg maintenance dose administered daily on The primary outcome measure was the time days 2 through 10 or until hospital discharge or to recovery, defined as the first day, during the death. A matching placebo was administered 28 days after enrollment, on which a patient according to the same schedule and in the same satisfied categories 1, 2, or 3 on the eight-cate- volume as the active drug. A normal saline pla- gory ordinal scale. The categories are as follows: cebo was used at the European sites and at some 1, not hospitalized, no limitations of activities; n engl j med nejm.org 2 The New England Journal of Medicine Downloaded from nejm.org on May 26, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved. Remdesivir for COVID-19 — Preliminary Report 2, not hospitalized, limitation of activities, home estimated number of recoveries needed for the oxygen requirement, or both; 3, hospitalized, not trial) and 81 deaths had been entered in the requiring supplemental oxygen and no longer re- database. At that time, the data and safety moni- quiring ongoing medical care (used if hospitaliza- toring board recommended that the preliminary tion was extended for infection-control reasons); primary analysis report and mortality data from 4, hospitalized, not requiring supplemental oxy- the closed safety report be provided to trial team gen but requiring ongoing medical care (Covid-19– members from the National Institute of Allergy related or other medical conditions); 5, hospital- and Infectious Diseases (NIAID). These results ized, requiring any supplemental oxygen; 6, were subsequently made public; the treating hospitalized, requiring noninvasive ventilation physician could request to be made aware of the or use of high-flow oxygen devices; 7, hospital- treatment assignment of patients who had not ized, receiving invasive mechanical ventilation or completed day 29 if clinically indicated (e.g., be- extracorporeal membrane oxygenation (ECMO); cause of worsening clinical status), and patients and 8, death. Other outcomes included mortality originally in the placebo group could be given at 14 and 28 days after enrollment and grade 3 remdesivir. This report summarizes the prelimi- and 4 adverse events and serious adverse events nary results from this ongoing trial.
Load more

Recommended publications
  • Virtual CROI 2021 Schedule at a Glance Version 3 (Short)
    virtual CROI 2021 Schedule at a Glance Version 3 (Short) LIVE PROGRAM TIME SATURDAY, MARCH 6, 2021 SUNDAY, MARCH 7, 2021 10:00 AM W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES OPENING SESSION (10:00 – 12:05) EST (10:00 – 14:00) CHAIRS WELCOME TO virtual CROI 2021 START Conveners: Serena S. Spudich and Nicolas Chomont Chairs: Sharon L. Hillier, James A. Hoxie, and Elaine J. Abrams ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 MARTIN DELANEY PRESENTATION LIVE PROGRAM Frank Kirchhoff INTRODUCTION ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY James Pickett Galit Alter VACCINE NATIONALISM IS KILLING US: HOW INEQUITIES IN RESEARCH AND ACCESS TO SARS-CoV-2 VACCINES WILL PERPETUATE THE PANDEMIC ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC Gregg S. Gonsalves and Fatima Hassan Jürgen Rockstroh BERNARD FIELDS LECTURE ADVANCES IN BIOMEDICAL PREVENTION OF HIV INTRODUCTION Jean-Michel Molina James A. Hoxie and Galit Alter ADVANCES IN HIV CURE NEUTRALIZING ANTIBODIES AGAINST CORONAVIRUSES Katherine J. Bar Pamela J. Bjorkman N'GALY-MANN LECTURE INTRODUCTION Elaine J. Abrams and Tedros Adhanom Ghebreyesus LESSONS FROM THE CONCURRENT HIV/AIDS AND COVID-19 PANDEMICS: A TWO-WAY STREET Anthony S. Fauci 12:20 PM CONCURRENT WORKSHOPS (12:20 – 2:20) EST W-2 FRONTIERS IN LABORATORY TECHNOLOGIES Conveners: Galit Alter and Frank Kirchhoff STRUCTURES OF SARS-CoV-2 ANTIBODIES INDUCED BY INFECTION AND mRNA VACCINES Christopher O. Barnes EMERGING CONCEPTS IN HIV-1 RESTRICTION Edward Campbell SARS-CoV-2 SPECIFIC AND CROSS-REACTIVE T CELL RESPONSES Daniela Weiskopf ARTIFICIAL INTELLIGENCE-INSPIRED ANTIBODY ENGINEERING Sai Reddy W-3 CLINICAL TRIAL DESIGN AND ANALYSIS Conveners: Susan P.
    [Show full text]
  • Supplementary Appendix
    Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 2020;382:1112-23. DOI: 10.1056/NEJMoa1904398 (PDF updated March 26, 2020) Susan Swindells, et al. Long-Acting Cabotegravir and Rilpivirine for HIV-1 (ATLAS Trial) SUPPLEMENTARY APPENDIX Contents Study Sites and Lead Investigators ............................................................................................................... 2 Eligibility Criteria ........................................................................................................................................... 6 Figure S1. Timeliness of Injections Relative to Target. ............................................................................... 14 Figure S2. Unadjusted Difference (LA Arm Minus CAR Arm) in Percentage Proportion with HIV-1 RNA ≥50 copies/mL at Week 48 (Snapshot) ± 95% CI. ............................................. 15 Figure S3. Incidence of Injection Site Reaction Adverse Events, LA Arm.................................................... 16 Table S1. Summary of Antiretroviral Agents Taken at Baseline. ................................................................ 17 Table S2. Reasons for Exclusion From the Per-Protocol Population .......................................................... 18 Table S3. Additional Secondary Endpoints ................................................................................................
    [Show full text]
  • Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know Jinoos Yazdany, MD, MPH, and Alfred H.J
    Annals of Internal Medicine IDEAS AND OPINIONS Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know Jinoos Yazdany, MD, MPH, and Alfred H.J. Kim, MD, PhD n the desperate search to find effective treatments mediated diseases is not. For example, HCQ is a Ifor coronavirus disease 2019 (COVID-19), 2 generic cornerstone of therapy for SLE. Hydroxychloroquine drugs, used largely by rheumatologists and dermatolo- can effectively treat disease manifestations, such as gists to treat immune-mediated diseases, have entered joint pain and rashes; reduce thrombotic events; and the spotlight. The antimalarials hydroxychloroquine prolong survival. Of note, landmark clinical trials have (HCQ) and chloroquine (CQ) have demonstrated anti- demonstrated that the withdrawal of HCQ can lead to viral activity against severe acute respiratory syndrome– flares of disease, including life-threatening manifesta- coronavirus 2 (SARS–CoV-2) in vitro and in small, poorly tions, such as lupus nephritis (8). The current shortages controlled or uncontrolled clinical studies (1–3). Nor- of HCQ have therefore alarmed rheumatologists and mally, such research would be deemed hypothesis- patients. Offices across the country report fielding calls generating at best. A tweet by President Trump on 21 from concerned patients who are having difficulty ob- March 2020 claiming that the combination of HCQ and taining their medication. azithromycin “ha[s] a real chance to be one of the big- Given the likelihood that shortages will continue in gest game changers in the history of medicine” accel- the near term, we propose that manufacturers, clini- erated a worldwide run on the drugs, with pharmacies cians, pharmacies, health systems, and governmental reporting shortages within 24 hours.
    [Show full text]
  • Supplementary Appendix
    Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. DOI: 10.1056/NEJMoa2007764 Supplementary Appendix to Manuscript Entitled Remdesivir for the Treatment of COVID-19 – Final Report Table of Contents: ACTT-1 Study Group ...................................................................................................................... 3 ACTT-1 Study Team Members ....................................................................................................... 8 Supplemental Methods: ................................................................................................................. 17 Additional Study Design Details ............................................................................................... 17 Additional Study population Details ......................................................................................... 17 Additional Study Procedures Details ........................................................................................ 18 Additional Statistical Analysis Details ...................................................................................... 19 Supplemental Tables and Figures: ................................................................................................ 20 Table S1. Categorical Demographic and Baseline Characteristics by Treatment Group ......... 20 Table
    [Show full text]
  • 1 CAPRI Adaptive Protocol Ver 3.0 7/26/2020 a Randomized Controlled
    A randomized controlled adaptive study comparing COVID-19 convalescent plasma to non-immune plasma to limit coronavirus-associated complications in hospitalized patients. IND # 21774 Protocol Chairs: Annie Luetkemeyer & Priscilla Hsue Version 3.0 7/26/2020 1 CAPRI Adaptive protocol Ver 3.0 7/26/2020 A randomized, controlled, adaptive study comparing COVID-19 convalescent plasma to non-immune plasma to limit coronavirus-associated complications in hospitalized patients. SIGNATURE PAGE I will conduct the study in accordance with the provisions of this protocol and all applicable protocol-related documents. I agree to conduct this study in compliance with United States (US) Health and Human Service regulations (45 CFR 46); applicable U.S. Food and Drug Administration regulations; standards of the International Conference on Harmonization Guideline for Good Clinical Practice (E6); Institutional Review Board/Ethics Committee determinations; all applicable in-country, state, and local laws and regulations; and other applicable requirements and institutional policies. Principal Investigator: _______________________________________________ Print/Type Signed: ___________________________________ Date: _____________ Name/Title 2 CAPRI Adaptive protocol Ver 3.0 7/26/2020 Contents 1 PROTOCOL TEAM ROSTER ............................................................................................................................................... 5 2 LIST OF ABBREVIATIONS ................................................................................................................................................
    [Show full text]
  • Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment November 16-17, 2016 Rockville, Maryland
    U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION HEALTH RESOURCES AND SERVICES ADMINISTRATION Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment November 16-17, 2016 Rockville, Maryland Record of the Proceedings TABLE OF CONTENTS Agenda Item Page MINUTES OF THE NOVEMBER 16-17, 2016 CHAC MEETING 1 Opening Session: November 16, 2016 2 Update by the Acting HRSA Administrator 5 HRSA/HAB Associate Administrator’s Report 8 CDC/NCHHSTP Director’s Report 13 People Living with HIV Leadership 20 PANEL PRESENTATION: ELIMINATING HCV 25 • Update on the 2017-2020 National Viral Hepatitis Action Plan 25 • CMS’s Role in the National Viral Hepatitis Response 27 • Overview of the San Francisco HCV Elimination Initiative 29 • Overview of the New Mexico HCV Elimination Collaborative 32 • Overview of NASTAD’s Technical Assistance for HIV/HCV Co-Infection 36 CDC New Surveillance Report ─ Changes in Analyzing the HIV Care Continuum 39 PANEL PRESENTATION: CMS, CDC, HRSA HIV HEALTH IMPROVEMENT AFFINITY 42 GROUP Public Comment Period 49 Update by the CHAC Viral Hepatitis Workgroup 51 Preparation for the CHAC Business Session 54 Opening Session: November 17, 2016 55 Leveraging Partnerships to Support Increased Employment/Educational 56 Opportunities for PLWH PANEL PRESENTATION: HIV AND AGING ─ IMPLICATIONS FOR HEALTH CARE, 60 MENTAL HEALTH, AND SUPPORT NEEDS Update by the CHAC Pre-Exposure Prophylaxis Workgroup 67 CHAC Business Session 70 • TOPIC 1: APPROVAL OF THE JUNE 2016 DRAFT CHAC MEETING MINUTES 70 • TOPIC 2: ESTABLISHMENT OF A NEW CHAC YOUTH WORKGROUP 70 • TOPIC 3: ESTABLISHMENT OF A NEW CHAC HIV AND AGING WORKGROUP 71 • TOPIC 4: DRAFT HCV RESOLUTION 72 • TOPIC 5: WORKFORCE DEVELOPMENT 76 • TOPIC 6: FUTURE AGENDA ITEMS 78 Closing Session 80 Attachment 1: Participants’ Directory 82 Attachment 2: Glossary of Acronyms 85 U.S.
    [Show full text]
  • A Computational Approach to Aid Clinicians in Selecting Anti-Viral Drugs for COVID-19 Trials
    A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials Aanchal Mongia1, Sanjay Kr. Saha2, Emilie Chouzenoux3∗ & Angshul Majumdar4∗ 1Dept. of CSE, IIIT - Delhi, India, 110020 2Department of Community Medicine, IPGMER Kolkata 3CVN, Inria Saclay, Univ. Paris Saclay, 91190 Gif-sur-Yvette, France 4Dept. of ECE, IIIT - Delhi, India, 110020 ∗Corresponding authors contact/Email: [email protected], [email protected] 3 July, 2020 Abstract Motivation: COVID-19 has fast-paced drug re-positioning for its treatment. This work builds computational models for the same. The aim is to assist clinicians with a tool for selecting prospective antiviral treatments. Since the virus is known to mutate fast, the tool is likely to help clinicians in selecting the right set of antivirals for the mutated isolate. Results: The main contribution of this work is a manually curated database publicly shared, comprising of existing associations between viruses and their corresponding antivirals. The database gathers similarity information using the chemical structure of drugs and the genomic structure of viruses. Along with this database, we make available a set of state-of-the-art computational drug re-positioning tools based on matrix completion. The tools are first analysed on a standard set of experimental protocols for drug target interactions. The best performing ones are applied for the task of re-positioning antivirals for COVID-19. These tools select six drugs out of which four are currently under various stages of trial, namely Remdesivir (as a cure), Ribavarin (in combination with others for cure), Umifenovir (as a prophylactic and cure) and Sofosbuvir (as a cure).
    [Show full text]